HRSA's decision to refer six drug manufacturers to the HHS OIG has elicited a variety of reactions.

Parties at Center of Contract Pharmacy Standoff React to HHS OIG Referral

The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to covered entities that use contract pharmacies drew praise from 340B provider groups and was roundly criticized by the drug companies and their primary lobbying group.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report